What about this statement is unclear about how they are funding their planned studies through 2015?

Quote:

---

Notwithstanding the tremendous fundamental growth the Company is experiencing, we recognize the primary concern to our investors is dilution. To this, I will note that we already have, within the existing cap structure as of today, access to $18M in financing from our Lincoln Park facility and $5M through the exercise of warrants. This capital would be sufficient to carry us into 2016.

---

And this is based on the original 1 Billion authorized shares, not the additional shares added with the shareholder vote. Nowhere in this statement was LymPro revenue a consideration.